Immune Phenotype As a Biomarker for Systemic Lupus Erythematosus

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2023 Jun 28

PMID 37371540

Authors

Shingo Nakayamada

Yoshiya Tanaka

Affiliations

Soon will be listed here.

Abstract

The treatment of rheumatoid arthritis was revolutionized with the use of molecular-targeted drugs that target immunoregulatory molecules. The success of treatment with these drugs prompted the development of molecular-targeted drugs for systemic lupus erythematosus. However, systemic lupus erythematosus is a disease with high heterogeneous immune abnormalities, and diverse cells or molecules can be treatment targets. Thus, the identification of subpopulations based on immune abnormalities is essential for the development of effective treatment. One analytical method used to identify subpopulations is the immunophenotyping of peripheral blood samples of patients. This analysis evaluates the validity of target molecules for peripheral blood immune cell subsets, which are expected to be developed as biomarkers for precision medicine in which appropriate treatment targets are set for each subpopulation.

Citing Articles

Association of peripheral CD8 T cell activation with disease activity and treatment resistance in systemic lupus erythematosus.

Fujita Y, Nakayamada S, Kubo S, Miyazaki Y, Sonomoto K, Tanaka H RMD Open. 2025; 11(1).

PMID: 40010940 PMC: 11865784. DOI: 10.1136/rmdopen-2024-005122.

Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system.

Balog J, Zvara A, Bukovinszki V, Puskas L, Balog A, Szebeni G Front Immunol. 2024; 15:1376933.

PMID: 38726007 PMC: 11079270. DOI: 10.3389/fimmu.2024.1376933.

References

Lanata C, Paranjpe I, Nititham J, Taylor K, Gianfrancesco M, Paranjpe M . A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nat Commun. 2019; 10(1):3902. PMC: 6715644. DOI: 10.1038/s41467-019-11845-y. View

Ronnblom L, Elkon K . Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010; 6(6):339-47. DOI: 10.1038/nrrheum.2010.64. View

Vinuesa C, Linterman M, Yu D, MacLennan I . Follicular Helper T Cells. Annu Rev Immunol. 2016; 34:335-68. DOI: 10.1146/annurev-immunol-041015-055605. View

Murphy G, Isenberg D . New therapies for systemic lupus erythematosus - past imperfect, future tense. Nat Rev Rheumatol. 2019; 15(7):403-412. DOI: 10.1038/s41584-019-0235-5. View

Hao H, Nakayamada S, Ohkubo N, Yamagata K, Zhang M, Shan Y . Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. Arthritis Res Ther. 2021; 23(1):302. PMC: 8665514. DOI: 10.1186/s13075-021-02682-w. View

Choi J, Ho J, G Pasoto S, Bunin V, Kim S, Carrasco S . Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. Arthritis Rheumatol. 2015; 67(4):988-99. PMC: 4450082. DOI: 10.1002/art.39020. View

Wang S, Wang J, Kumar V, Karnell J, Naiman B, Gross P . IL-21 drives expansion and plasma cell differentiation of autoreactive CD11cT-bet B cells in SLE. Nat Commun. 2018; 9(1):1758. PMC: 5931508. DOI: 10.1038/s41467-018-03750-7. View

Tanaka Y . State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis. 2020; 23(4):465-471. PMC: 7187183. DOI: 10.1111/1756-185X.13817. View

Wollenberg I, Agua-Doce A, Hernandez A, Almeida C, Oliveira V, Faro J . Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J Immunol. 2011; 187(9):4553-60. DOI: 10.4049/jimmunol.1101328. View

10.

Gravallese E, Firestein G . Rheumatoid Arthritis - Common Origins, Divergent Mechanisms. N Engl J Med. 2023; 388(6):529-542. DOI: 10.1056/NEJMra2103726. View

11.

Xu B, Wang S, Zhou M, Huang Y, Fu R, Guo C . The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin Immunol. 2017; 183:46-53. PMC: 5673570. DOI: 10.1016/j.clim.2017.07.004. View

12.

Tsubata T . B-cell tolerance and autoimmunity. F1000Res. 2017; 6:391. PMC: 5373417. DOI: 10.12688/f1000research.10583.1. View

13.

Wallace D, Gudsoorkar V, Weisman M, Venuturupalli S . New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012; 8(9):522-33. DOI: 10.1038/nrrheum.2012.106. View

14.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

15.

Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y . Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis. 2018; 77(9):1354-1361. DOI: 10.1136/annrheumdis-2017-212652. View

16.

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

17.

Liu C, Wang D, Song Y, Lu S, Zhao J, Wang H . Increased circulating CD4CXCR5FoxP3 follicular regulatory T cells correlated with severity of systemic lupus erythematosus patients. Int Immunopharmacol. 2018; 56:261-268. DOI: 10.1016/j.intimp.2018.01.038. View

18.

Crotty S . T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014; 41(4):529-42. PMC: 4223692. DOI: 10.1016/j.immuni.2014.10.004. View

19.

Patel Z, Lu X, Miller D, Forney C, Lee J, Lynch A . A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet. 2018; 27(13):2392-2404. PMC: 6005081. DOI: 10.1093/hmg/ddy140. View

20.

Parish C, Glidden M, Quah B, Warren H . Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr Protoc Immunol. 2009; Chapter 4:4.9.1-4.9.13. DOI: 10.1002/0471142735.im0409s84. View